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Introduction
The recent publication of two draft sequences for the
human genome, together with rapidly increasing knowl-
edge of the extent of genetic variability between individuals
available from resources such as the SNP Consortium (in
which SNP stands for single-nucleotide polymorphism),
has major implications for the study of respiratory disease.
Genetic variability between individuals in drug-metabolising
enzymes or in the primary targets for drugs might account
in part for inter-individual variability in treatment response.
Research in this area is covered by the broad term pharma-
cogenetics. In addition, knowledge of the primary
sequence of the approximately 30,000 genes in the human
genome will permit the identification of novel genes that
might be important in disease aetiology or progression and
might be potential targets for therapeutic agents. Expres-
sion-profiling approaches to the identification of targets for
new treatments is covered by the broad term pharmacoge-
nomics. This review covers some of the fundamental issues
important in these two developing branches of research.
Pharmacogenetics
Polymorphic variation in the human genome
Genetic variability at the DNA level occurs in approxi-
mately 1 in 500 to 1 in 1000 bases of coding DNA and in
1 in 300 to 1 in 500 bases in non-coding DNA [1]. These
rates are averages across the human genome but it is
clear that, when specific short regions of DNA are consid-
ered, the rates of polymorphism can be much higher or
lower. The vast majority of variation is due to substitutions
of one base at a specific site (i.e. an SNP). However, other
variations are possible, including deletions, insertions and
the expansion of tandem repeat sequences. One impor-
tant consequence of the insertion or deletion of even a
single base pair within coding regions is the subsequent
frame shift introduced downstream. Because the amino
acid sequence of a protein is determined at the DNA level
by groups of three base pairs coding for each amino acid,
introducing a single additional base changes the ‘reading
frame’ downstream of this site, thus resulting in an alter-
ation in the amino acid sequence in the protein. This
Review
Pharmacogenetics, pharmacogenomics and airway disease
Ian P Hall
Queens Medical Centre, Nottingham, UK
Correspondence: Professor Ian P. Hall, Division of Therapeutics, C Floor, South Block, Queens Medical Centre, Nottingham, UK. 
Tel: +44 115 970 9985; fax: +44 115 942 2232; e-mail: ian.hall@nottingham.ac.uk
Abstract
The availability of a draft sequence for the human genome will revolutionise research into airway
disease. This review deals with two of the most important areas impinging on the treatment of patients:
pharmacogenetics and pharmacogenomics. Considerable inter-individual variation exists at the DNA
level in targets for medication, and variability in response to treatment may, in part, be determined by
this genetic variation. Increased knowledge about the human genome might also permit the
identification of novel therapeutic targets by expression profiling at the RNA (genomics) or protein
(proteomics) level. This review describes recent advances in pharmacogenetics and
pharmacogenomics with regard to airway disease.
Keywords: asthma, chronic obstructive pulmonary disease, expression profiling, pharmacogenetics,
pharmacogenomics, proteomics, single-nucleotide polymorphism
Received: 8 May 2001
Revisions requested: 6 June 2001
Revisions received: 23 October 2001
Accepted: 23 October 2001
Published: 26 November 2001
Respir Res 2002, 3:10
The complete version of this article is available online at
http://respiratory-research.com/content/3/2/?
© 2002 BioMed Central Ltd
(Print ISSN 1465-9921; Online ISSN 1465-993X)
Page 1 of 6
(page number not for citation purposes)Page 2 of 6
(page number not for citation purposes)
Respiratory Research    Vol 3 No 1 Hall
frameshift will also disrupt downstream stop codons such
that the protein might be truncated or extended, depend-
ing on where new stop codons occur.
The functionality of any given polymorphism depends on
its nature and position. Thus SNPs in non-coding
regions are likely to be non-functional in the main,
although if they either interfere with recognised consen-
sus sequences for the binding of transcription factors or
alter enhancer elements or splice signals they can have
effects on the level of expression of downstream genes.
Within coding regions, SNPs are more likely to have
functional effects if they occur in the first or second base
pair of a codon; redundancy in the amino acid coding
system means that the third base pair can in some cases
be altered without changing the amino acid sequence of
the protein. Thus, polymorphism at the DNA level can be
either synonymous or non-synonymous, the latter imply-
ing that the polymorphism produces an amino acid sub-
stitution in the relevant protein.
Amino acid substitutions themselves can be considered to
be conservative or non-conservative, depending on
whether they alter the charge or the size of the substituted
group. Again, one can predict that non-conservative amino
acid substitutions would be more likely to have a direct
functional effect than conservative substitutions because
the three-dimensional structure of the protein or the
charge distribution around important functional epitopes is
more likely to be affected. As mentioned above, insertions
and/or deletions are more likely than SNPs to produce
functional effects within coding regions because they will
disrupt the amino acid sequence of the protein.
Although most SNPs within the human genome are
unlikely to produce functional effects directly, they can still
be used as markers for genes of interest. This is because
linkage disequilibrium extends over short distances [2] in
the human genome, even in outbred populations; thus
polymorphisms within the immediate vicinity of a given
gene are likely to be non-randomly associated. Although
many studies so far have used individual SNPs or other
polymorphisms to assess functional end points (such as a
clinical response in a phase 3 trial), the use of a nonfunc-
tional polymorphism as a marker will give useful informa-
tion only if that marker is in relatively tight linkage
disequilibrium with the functionally relevant polymorphisms
within the gene of interest. This could occur in two ways.
Firstly, a single mutation with a marked functional effect
might have associated SNPs nearby, which will also show
association with clinical end points because of linkage dis-
equilibrium. In this situation the tightest association would
be with the functionally relevant polymorphism, with asso-
ciation weakening as SNPs farther from the functionally
important polymorphism are considered.
Secondly, multiple polymorphisms, each with a relatively
small effect, might occur in combinations in which the
combination has a particularly deleterious or beneficial
associated phenotype. In this case haplotype analysis (i.e.
looking at combinations of polymorphisms across the site)
will give the most accurate information.
In practice, one would predict that linkage disequilibrium
would be directly related to the distance between individ-
ual markers. However, this is not necessarily always true,
presumably because of the different evolutionary time
points at which polymorphisms have arisen and random
differences in the rate of genetic drift, so that one can
sometimes see tighter linkage disequilibrium with markers
that are not adjacent than with adjacent markers (see, for
example, [3]). In addition, recombination rates vary across
genomic regions.
Pharmacogenetics of airway treatment targets
Several primary targets for treatment of airway disease
have been screened for polymorphic variation. The major-
ity of data are from Caucasian populations and it is impor-
tant to remember that differences in the prevalence of
given polymorphisms can occur when populations with
different ethnic backgrounds are studied. The main targets
of currently available drugs which have been screened for
polymorphic variation are shown in Table 1.
It is immediately clear that whereas some primary targets
contain extensive polymorphic variation (such as the β2
adrenoceptor) [4,5], others show far fewer degrees of
polymorphism (such as the muscarinic M3 receptor).
Whereas for these less polymorphic genes there might be
polymorphic variation in regulatory regions or in different
population groups that have not yet been adequately
studied, it seems that large differences in the amount of
variability can exist in genes of similar sizes. The explana-
tion for this is unclear but the variability is unlikely to be
accounted for by evolutionary history (in other words, the
time at which the receptor subtype or enzyme isoform
arose). One possible explanation is that at least some of
these variants have been driven by selection pressures
(such as resistance to infection), although obviously this
would not be related to treatment response in itself. There
might also be selective constraints on given genes, result-
ing in lower or higher rates of variation occurring within
them.
For airway disease targets, by far the best-studied primary
target is the human β2-adrenoceptor. This is known to
contain at least 17 SNPs within a 3-kilobase region includ-
ing its regulatory regions and coding region [4–6]. Five of
the nine polymorphisms in the coding region are degener-
ate but four result in amino acid substitutions within the
protein [4]. Expression studies in which the different poly-
morphic variants of the receptor have been expressed inPage 3 of 6
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fibroblast lines have shown altered agonist binding
(Thr164→Ile variant) [7] and altered downregulation pro-
files (Arg16→Gly; Gln27→Glu) [8]. Studies with cultured
airway smooth muscle isolated from human lungs have
shown similar data, at least for the codon 16 and 27 vari-
ants, although analysis is complicated by linkage disequi-
librium effects with other polymorphisms within this locus
in these constitutively expressing systems [9], and not all
published data are consistent [10].
Many clinical studies have now been performed that
examine the potential effects of these polymorphisms
[11–25] and in general they have shown relatively small
effects, although there are reasonably convincing data
supporting reduced bronchodilator responses in individu-
als carrying the Gly16 allele [13,16,17,25]. However,
recent studies have suggested that the haplotype across
this region might in fact be the most important determinant
of response [6] . If this proved to be correct, it would imply
that the second of the models discussed above for multi-
ple polymorphisms within a locus seems to hold true for
this gene. Whether or not treatment response can be ade-
quately predicted prospectively by a knowledge of geno-
type and/or haplotype remains to be formally established.
The second gene for which reasonable data exist is the
gene coding for 5-lipoxygenase. Insertions or deletions
within the promoter region for this gene, which encodes
recognition sites for the transcription factor SP1, alter the
level of transcription of the 5-lipoxygenase gene and
hence the 5-lipoxygenase activity present within tissue
[26–28]. In a study with a 5-lipoxygenase inhibitor,
response to treatment was shown to be related to geno-
type; individuals having alleles associated with low tran-
scriptional activity of the gene showed little or no
response to treatment with a 5-lipoxygenase inhibitor [27].
Preliminary data suggest that clinical response to Cys-
leukotriene receptor antagonists might also be predicted
by this polymorphism.
Data on the majority of other primary airway targets are
less extensive and few clinical studies have been per-
formed so far. Certainly for some targets it seems unlikely
that clinical response is related to genetic variation; the
muscarinic M3 receptor has not so far been found to
contain any common coding-region polymorphisms [29]
and the extent of polymorphic variation within both the his-
tamine H1 receptor and the Cys-leukotriene 1 receptor is
much lower than that of the β2 adrenoceptor [30]. In con-
trast, aspirin-sensitive asthma has been linked to a poly-
morphism in the leukotriene C4 synthase gene, and some
supporting evidence exists at a clinical level [31].
One attractive target for pharmacogenetic studies is the
glucocorticoid receptor. Perhaps surprisingly, given clear
evidence of variable response to glucocorticoids (particu-
larly in asthma), relatively little is known about genetic vari-
ability in the receptor and response to treatment. One
nondegenerate polymorphism (Asp363→Ser) has been
identified, but this is relatively rare; nevertheless, individu-
als with this polymorphism might be expected to show an
enhanced response [32]. No mutations predicting gluco-
corticoid ‘resistance’ have yet been identified [33,34].
In addition to the primary target for drugs, downstream
signalling pathways will also contain proteins that might
show polymorphic variation. Far less is known about the
potential contribution of these components to pharmaco-
genetic variability at present. However, it seems likely that
the true profile of an individual in terms of response to a
given agent is determined by a combination of a polymor-
phic variation present at different parts of the signal trans-
duction cascade mediating the effect of that drug.
Preliminary evidence that this is important can be seen
Available online http://respiratory-research.com/content/3/1/10
Table 1
Selected genes in which polymorphic variation could contribute to variability in treatment response in asthma (adapted from [39])
Gene Chromosomal location Potential treatment response affected
β2-adrenoceptor (ADBR2) 5q31.32 β2-agonists (e.g. salbutamol, salmeterol)
5-LOX (ALOX5) 10q11.12 5-LOX inhibitors (e.g. zileuton), CysLT1 antagonists (e.g. zafirlukast
M2 receptor (CHRM2) 7q35.36 Muscarinic antagonists (e.g. ipratropium bromide)
M3 receptor (CHRM3) 1q43.44 Muscarinic antagonists (e.g. ipratropium bromide)
GR (GRL) 5q.31 Glucocorticoids (e.g. prednisolone, Beclomethasone)
PDE4A (PDE4A) 19p13.2 Theophylline
PDE4D (PDE4D) 5q12 Theophylline
CYP450 Various Montelukast, salmeterol, budesonide, Theophylline
5-LOX, 5-lipoxygenase; CYP450, cytochrome P450; GR, glucocorticoid receptor; PDE, phosphodiesterase.from information on the interleukin-4 (IL-4) system. Poly-
morphic variation exists in the IL-4 gene itself, in the α
subunit of the receptor (IL-4Rα) and in downstream sig-
nalling pathways (reviewed in [35]). Thus, the true pheno-
type of an individual in terms of his or her IL-4
responsiveness probably depends on a combination of
genetic variables in all of these components of the signal
transduction pathway.
One further important aspect of pharmacogenetics in
general is the influence of polymorphism in drug-
metabolising enzymes on pharmacokinetics (reviewed in
[36]). For most airway drugs, cytochrome P450 polymor-
phism is relatively unimportant in clinical terms, although
there are data to show that nicotine dependence is con-
trolled in part by cytochrome P450 2D6 status [37].
Pharmacogenomics
Whereas pharmacogenetics deals with the influence of
genetic variability on treatment response or the risk of
serious adverse reactions to drugs, pharmacogenomics
involves using molecular approaches to identify potential
novel targets for drug design. Traditionally, drug discovery
programmes have been based on the high-throughput
screening of likely targets with the aim of identifying small-
molecule antagonists or agonists at appropriate targets.
Obviously this approach requires a prior knowledge of the
target. However, many of the 30,000 genes within the
human genome code for novel proteins that could also be
important targets for drug development. Without prior
knowledge of the function of these gene products, classi-
cal pharmacological approaches are not feasible. Pharma-
cogenomic approaches are designed to identify which
novel gene products might potentially be important.
The recent description of a draft sequence for the human
genome will provide a further impetus to studies in this
area [1].
Current approaches to pharmacogenomics depend on
comparing expression profiles at the RNA (genomics) or
protein (proteomics) level for a given tissue or cell type
after a relevant stimulus. In principle this approach can be
used to explore which genes are upregulated or downreg-
ulated in an inflamed airway by comparing the expression
profiles in tissue taken from affected and unaffected indi-
viduals. The potential difficulty with this approach is that
small variations in the cellular constituents of the tissue
might produce large fluctuations in RNA and/or protein,
giving rise to false positive (or negative) data.
Another problem is that the logistical difficulties of dealing
with data on many gene products (which by definition
have no known function) are considerable. These prob-
lems can be avoided to some extent by simplifying the
experimental paradigm. For example, one approach that
our group has recently adopted is to use cultured human
airway smooth muscle cells from a single individual and
then to compare expression profiles after treatment with
pro-inflammatory and anti-inflammatory drugs.
A third approach is to attempt to combine classical
genetic and pharmacogenomic methodologies. For
example, one could examine the expression profile of novel
genes in tissue from individuals with and without a respira-
tory disease (such as asthma) and then prioritise those
novel gene products identified by studying genes that map
to regions of potential linkage from the genome screens
that have been performed so far. This approach presup-
poses that drug targets are likely to be genes important in
the initiation of the diseases itself (otherwise they would
not be identified in genome screen approaches).
RNA profiling
The concept of comparing expression profiles at the RNA
level is not new, and differential-display approaches have
been around for at least 10 years. The difficulty with the
original approaches was, however, that it was time-con-
suming and problematic to identify potentially novel tran-
scripts. The field has moved rapidly forwards with the
development of arrays of sequence-verified clones relating
to genes in the human genome that have been identified
as a result of the human genome project [38]. These
arrays can be made on membranes, on glass slides or on
‘chips’. The approach here is to hybridise RNA extracted
from the tissue or cell, with or without disease or treat-
ment, on parallel arrays and then to compare their expres-
sion profiles. At present the availability of arrays is heavily
dependent on the commercial sector, with many compa-
nies having in-house databases detailing the sequences
relating to their arrays. It is to be hoped that, with time, this
information will increasingly be held in the public domain.
The capacity for profiling novel genes is extremely high,
with micro-arrays or chips often holding several thousand
clones. The unit cost of performing these kinds of experi-
ment is also falling rapidly, with the result that the technol-
ogy will be available to many more investigators in the
academic sector.
Protein profiling
Although a knowledge of RNA expression profiles is
clearly important, a knowledge of change at the protein
level, be it either in the amount of protein produced or in
post-translational modifications, is a step closer to true
function. This has led to the development of methods to
assess protein expression profiles from cell or tissue
lysates. Again, tissue or cells from diseased and unaf-
fected individuals are used to prepare protein lysates, and
the expression profiles are compared. Methods for identi-
fying novel proteins are less advanced than for examining
RNA expression profiles but rapid progress is neverthe-
less being made in this field. The standard method is to
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teins and then to select proteins whose abundance or
mobility changes significantly. These proteins can then be
cored from the gel and mass spectrometry used to obtain
a signature that leads to identification of the protein in
about one-third of cases. These approaches are techni-
cally quite difficult and time-consuming. Several compa-
nies are working on methods to create arrays of proteins
analogous to the complementary DNA arrays used for
RNA expression profiling. In theory it should be possible to
generate protein arrays or chips by displaying monoclonal
antibodies recognising a wide range of proteins; such
approaches are currently under development.
Practical considerations
Although the pharmacogenomic approaches described
here provide an obvious potential way of identifying
novel genes important in a disease or in a treatment
response, there are several practical difficulties that must
be considered.
Firstly, it is critical to design the functional experiments
carefully. For example, if a cell is to be treated with a given
pro-inflammatory mediator and expression profiles are
compared either at the RNA or protein level, a reasonable
number of paired replicates must be performed and rele-
vant time points examined. In practice it might be possible
to reduce this to a base line and two different time points
for this kind of experiment; however, even then, with an
appropriate number of replicates the number of samples
to be processed remains considerable. It goes without
saying that expression profile data generated from poorly
designed experiments are likely to be at best worthless
and at worst misleading.
Secondly, a decision must be made on what to do with
the novel targets identified. Initially, verification is needed
and this is probably best done by using the reverse-tran-
scriptase-mediated polymerase chain reaction in a quanti-
tative manner.
Thirdly, the real challenge, having verified a target, is to
move from knowledge of a novel gene product to knowl-
edge of its function. As discussed above, some method of
prioritising targets to be studied further is critically impor-
tant at this stage. At present the use of these techniques
to study respiratory disease is in its relative infancy,
although in other disease areas (such as oncology) novel
gene products are being identified that are likely to be
important in disease pathophysiology.
Conclusion
This review has summarised how genetic approaches can
be used to identify novel drug targets and, potentially, to
optimise treatment response. Over the next 10 years it will
become clear whether these approaches are likely to be
cost effective either in the development of new drugs or in
optimising prescribing drugs for individual patients with
given diseases.
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